No Data
No Data
Peak Bio's Strategic Merger With Akari Therapeutics
Shareholder Alert: Ademi LLP Investigates Whether Peak Bio Inc. Has Obtained a Fair Price in Its Transaction With Akari
MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here
Akari Therapeutics Rises on All Stock Deal With Peak Bio
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
No Data